# Life sciences: what the register shows the world
The Dutch trade register carries the same fields for a life sciences company as for any other entity: name, registered activity code, directors, registered address. What is specific to this sector is what those fields typically hold, and what never reaches them at all: a pharmaceutical or biotechnology activity code, a capital table fragmented across successive funding rounds, and licensing or research agreements that stay entirely private. This page is for a counterparty, investor or adviser checking what a Dutch life sciences entity actually discloses before relying on it.
Why this arises here
A life sciences company is rarely one legal entity doing one thing. A Dutch group in this sector typically separates the operating company that runs research or manufacturing from the entity that holds patents and know-how, and from the entity that signs licensing deals with a commercial partner. Each of these sits within corporate law and governance as a filing question before it is anything else: which entity is actually registered to do what, and does the register match the group's own description of itself.
The commercial substance, the licence terms, the milestone payments, the research collaboration scope, is agreed by contract and never filed anywhere public. The register shows the corporate wrapper. It does not show what is inside it.
The mechanics in short
Three registrations matter for a Dutch life sciences entity, and each shows something different.
The trade register held by the Chamber of Commerce carries the entity's registered activity code, its directors, its registered address and, depending on size class, its filed annual accounts. A pharmaceutical or biotechnology code on the entry is a reliable indicator of the entity's stated business. It is not proof of what the entity is actually doing on the ground.
The UBO register carries the natural person or persons holding more than the statutory interest threshold in the entity, or, where no natural person crosses that threshold, a statutory alternative registration of a senior managing official. Life sciences ventures financed through several successive equity rounds routinely land in the second category.
A pledge over receivables or movable assets, where the parties want a fixed date attached to it, is commonly registered with the tax authority for that purpose alone. That registration confirms a pledge exists on a given date. It says nothing about what the pledge secures or on what terms.
The pattern specific to life sciences
The situation that arises here and does not arise the same way elsewhere is the dispersed cap table. A biotech or medtech venture that has closed several funding rounds, each bringing in a fund holding a minority stake, frequently has no single natural person above the UBO threshold. The register then falls back to registering a director as the statutory alternative. Read on its own, that entry looks like the director owns the company. It does not. Anyone relying on the UBO register for this sector has to check the size and structure of the cap table behind it, not just the name printed in the register.
Compare that with what appears on the equivalent page for logistics and transport filings, where ownership is typically concentrated and the fleet or licence sits with a single operating entity. The same register, read the same way, tells a different story because the underlying pattern of ownership is different. The distinction is not the sector label. It is what the sector actually does with its capital structure.
A second point specific to this sector: the register is silent on clinical development status. Whether a product is in preclinical work, in a clinical trial, or awaiting marketing authorisation is tracked in separate, non-corporate registers entirely outside the trade register and outside this firm's scope. A licensing dispute over a missed development milestone, if it escalates, is decided under Dutch law and, where the parties are in the Netherlands, before a Dutch court, but that dispute sits in the contract, never in the corporate filing.
What to check
- The registered activity code against what the entity actually does, not against the group's own marketing description of itself.
- Whether the UBO entry names a natural person above the threshold or falls back to a statutory alternative registration, and, if the latter, why.
- Whether a pledge is registered against the entity's receivables or IP-related assets, and whether that registration is current.
- The share classes in the deed of incorporation. Preference shares from a funding round change what a stated shareholding actually controls.
- Whether the filing entity is the one that holds the licence, the patent, or neither, and where the substance of the agreement actually sits.
Where a licensing dispute or a breach of a research collaboration escalates before it reaches this stage, the relevant procedural question resembles interim relief in an industrial manufacturing dispute: the register will not tell you whether urgent relief is available, only whether the entity you are dealing with is the one that can actually be bound.
What the register shows, by element
| Filing element | Where it is recorded | What it shows for a life sciences entity | What it does not show |
|---|---|---|---|
| Trade register entry | Chamber of Commerce | Name, activity code, directors, registered address | The substance of any licence or collaboration agreement |
| UBO register | Chamber of Commerce, restricted access to parts of the record | Natural person above the threshold, or a statutory alternative registration | Which fund holds which slice of a fragmented cap table |
| Pledge registration | Tax authority, for date-stamping purposes | That a pledge exists on a stated date | The security terms, the secured amount, or the underlying asset's licensing status |
| Filed annual accounts | Chamber of Commerce, per statutory size class | Aggregate revenue lines, which may include licensing income | Licensing income broken out from other revenue |
What this does not cover
- Clinical trial registration and marketing authorisation status: these sit in separate regulatory registers, not the corporate filing.
- The commercial terms of any licence, collaboration or supply agreement: none of it is public.
- Patent grant status and scope: this is a patent register question, not a corporate filing question.
- Sanctions, export control or dual-use classification of a specific product: a distinct compliance question outside this page.
- Advice on any specific transaction. This page describes the pattern, not your entity.
Questions
Does a pharmaceutical activity code on the trade register confirm the company is actively manufacturing?
No. The code reflects the registered activity as declared, not verified operational status. It is a starting point for a check, not the conclusion of one.
Why does a life sciences company's UBO entry sometimes name a director rather than an investor?
Where no natural person holds more than the statutory threshold, commonly the case after several funding rounds, the register falls back to a statutory alternative registration of a senior managing official rather than leaving the entry blank.
Where would a licence dispute between a Dutch life sciences entity and its commercial partner be decided?
Under Dutch law, and, where the parties and the dispute are connected to the Netherlands, before a Dutch court, unless the licence agreement itself provides for arbitration or another forum.
Sanne de Wit works on structures, holding arrangements and tax questions at Nolthenius & Partners. Her work on this page concerns how a Dutch life sciences group's filings correspond, or fail to correspond, to its actual capital and licensing structure.
For groups with the pattern described above, the Beklamel standard applied to group companies is the relevant question once a director's registered position and a fund's actual control diverge. A structure report maps the entity's registered activity code, its filed pledges, and its UBO entry as they stand on the day it is run, which is the starting point before running a structure report ahead of a settlement negotiation. This sits within the firm's corporate governance and filings work.
Last legal review: 2026-09-28